아토피 피부염 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 약제 클래스별, 투여 경로별, 지역별 세분화 및 경쟁 구도(2020-2030년)
Atopic Dermatitis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Region and Competition, 2020-2030F
상품코드:1879299
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 아토피 피부염 치료제 시장은 2024년에 145억 2,000만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 8.83%로 성장하여 241억 2,000만 달러에 이를 것으로 예측됩니다.
세계 아토피 피부염 치료제 시장은 심한 가려움증과 습진성 병변을 특징으로 하는 만성 염증성 피부질환인 아토피피부염의 관리를 목적으로 하는 의약품으로 구성되어 있습니다. 시장 확대를 뒷받침하는 주요 요인으로는 전 세계적인 질병 유병률 증가, 질병 병태생리에 대한 이해의 획기적인 진전으로 인한 새로운 표적치료제 개발, 조기 치료 시작을 가능하게 하는 진단 능력의 향상 등을 들 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
145억 2,000만 달러
시장 규모 : 2030년
241억 2,000만 달러
CAGR : 2025-2030년
8.83%
성장 속도가 가장 빠른 부문
생물학적 제제
최대 시장
북미
주요 시장 성장 촉진요인
주요 시장 과제
주요 시장 동향
개인 맞춤형 의료 및 바이오마커 기반 치료법
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 아토피 피부염 치료제 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
약제 클래스별(생물학적 제제, PDE4 억제제, 코르티코스테로이드, 칼시뉴린 억제제)
투여 경로별(외용, 주사, 경구)
지역별
기업별(2024년)
시장 맵
제6장 북미의 아토피 피부염 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 아토피 피부염 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 아토피 피부염 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 아토피 피부염 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
남아프리카공화국
제10장 남미의 아토피 피부염 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(M&A)
제품 출시
최근 동향
제13장 세계의 아토피 피부염 치료제 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Abbvie, Inc.
Bausch Health Companies Inc.
Nestle India Limited
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Evelo Biosciences, Inc.
Cara Therapeutics Inc.
Bristol-Myers Squibb Company
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Atopic Dermatitis Drugs Market, valued at USD 14.52 Billion in 2024, is projected to experience a CAGR of 8.83% to reach USD 24.12 Billion by 2030. The global atopic dermatitis drugs market comprises pharmaceutical interventions designed to manage atopic dermatitis, a chronic inflammatory skin condition characterized by intense pruritus and eczematous lesions. Key drivers supporting market expansion include the increasing global prevalence of the disease, significant advancements in understanding disease pathophysiology leading to the development of novel targeted therapies, and improved diagnostic capabilities facilitating earlier treatment initiation.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 14.52 Billion
Market Size 2030
USD 24.12 Billion
CAGR 2025-2030
8.83%
Fastest Growing Segment
Biologics
Largest Market
North America
Key Market Drivers
The increasing global prevalence of atopic dermatitis profoundly influences the pharmaceutical market by continually expanding the patient population requiring advanced therapeutic solutions. This chronic inflammatory skin condition manifests across all demographics, generating persistent demand for effective drug interventions capable of managing diverse disease severities. The expanding patient pool necessitates a broader portfolio of medications to alleviate symptoms and address underlying immunological dysregulation.
Key Market Challenges
The high cost associated with advanced therapeutic agents, particularly biologics and Janus kinase inhibitors, significantly impedes the growth of the global atopic dermatitis drugs market. These substantial expenses create considerable reimbursement hurdles for healthcare systems and often result in restricted patient access to these critical medications. This limitation directly slows market expansion by preventing a broader patient population from initiating or continuing effective advanced treatments, despite clinical need. The financial burden impacts both individual patients, who may face high out-of-pocket costs, and payers, who implement stringent coverage criteria.
Key Market Trends
Personalized Medicine and Biomarker-Guided Therapies
This trend fundamentally reshapes the global atopic dermatitis drugs market by fostering treatments tailored to individual patient profiles. Leveraging biomarkers and genetic insights, this precision approach aims to enhance therapeutic efficacy and minimize adverse reactions, optimizing patient outcomes. The Canadian Dermatology Foundation, in 2025, supported this direction by offering Innovation Grants of up to $100,000 over two years for dermatology research projects. Furthermore, Eli Lilly announced in March 2024 results from a lebrikizumab study specifically for people with skin of color and moderate-to-severe atopic dermatitis, evaluating 50 patients with darker skin tones. This signifies the market's evolution towards precise, demographic-specific therapeutic solutions.
Key Market Players
Abbvie, Inc.
Bausch Health Companies Inc.
Nestle India Limited
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Evelo Biosciences, Inc.
Cara Therapeutics Inc.
Bristol-Myers Squibb Company
Report Scope:
In this report, the Global Atopic Dermatitis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Atopic Dermatitis Drugs Market, By Drug Class:
Biologics
PDE4 Inhibitors
Corticosteroids
Calcineurin Inhibitors
Atopic Dermatitis Drugs Market, By Route of Administration:
Topical
Injectable
Oral
Atopic Dermatitis Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Atopic Dermatitis Drugs Market.
Available Customizations:
Global Atopic Dermatitis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Atopic Dermatitis Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Biologics, PDE4 Inhibitors, Corticosteroids, Calcineurin Inhibitors)
5.2.2. By Route of Administration (Topical, Injectable, Oral)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Atopic Dermatitis Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of Administration
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Atopic Dermatitis Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.2. Canada Atopic Dermatitis Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.3. Mexico Atopic Dermatitis Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
7. Europe Atopic Dermatitis Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Atopic Dermatitis Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.2. France Atopic Dermatitis Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.3. United Kingdom Atopic Dermatitis Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.4. Italy Atopic Dermatitis Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.5. Spain Atopic Dermatitis Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
8. Asia Pacific Atopic Dermatitis Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Atopic Dermatitis Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.2. India Atopic Dermatitis Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.3. Japan Atopic Dermatitis Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.4. South Korea Atopic Dermatitis Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.5. Australia Atopic Dermatitis Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
9. Middle East & Africa Atopic Dermatitis Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Atopic Dermatitis Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.2. UAE Atopic Dermatitis Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.3. South Africa Atopic Dermatitis Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
10. South America Atopic Dermatitis Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Atopic Dermatitis Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.2. Colombia Atopic Dermatitis Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.3. Argentina Atopic Dermatitis Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Atopic Dermatitis Drugs Market: SWOT Analysis
